Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a ...

Sanofi, Formation Bio and OpenAI have joined forces to build ... “At scale, this AI-driven development approach can ...

Please find enclosed a copy of the Postal Ballot Notice together with the Explanatory Statement for your record. We have also enclosed the Calendar of Events for the Postal Ballot process for your ...

To combat this, allergy medication Allegra created Allegra Airways, a website designed to help find and map real-time routes ...

Sanofi could announce the deal with buyout firm CD&R as soon as early next week, according to the people. The consumer health unit, known as Opella, is set to be valued at around €15 billion ...